蒙特卢卡斯特在患有腺增大症的儿童中的作用 - - 一项比较研究
Binayak Baruah1, Ajay Gupta1, Abhijit Kumar1
1Tata Main Hospital, Bistupur, 831001 Jamshedpur, Jharkhand India.
概括
口服蒙特卢卡斯特有效地减少了儿童腺缩症状. 这种非手术疗法为腺切除术提供了可行的替代方案,改善了打,睡眠和呼吸.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 儿科肺病学 儿科肺病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 腺体缩 (AH) 导致鼻腔阻塞和阻塞性睡眠呼吸暂停.
- 手术腺切除术有诸如出血和复发等并发症.
- 目前正在探索对AH的非手术治疗方法.
研究的目的:
- 评估口服蒙特卢卡斯特在患有AH的儿童中的疗效.
- 评估蒙特卢卡斯特对AH症状和腺大小的影响.
主要方法:
- 60名患有AH的儿童 (6-12岁) 被随机分配到蒙特卢卡斯特和安慰剂组.
- 治疗持续时间为12周,每天服用5毫克蒙特卢卡斯特或安慰剂.
- 症状严重程度,腺鼻比率 (X射线) 和内镜分数在治疗前和后被评估.
主要成果:
- 打,睡眠不适或口腔呼吸没有显著的基线差异.
- 在蒙特卢卡斯特组中,治疗后 significant 显著改善了打 (P<0.006),睡眠不适 (P<0.001) 和口腔呼吸 (P<0.001).
- 蒙特卢卡斯特证明了腺体大小和症状严重程度的减少.
结论:
- 口服蒙特卢卡斯特在治疗儿童腺增大时有效.
- 蒙特卢卡斯特可以减少腺的尺寸,并改善相关症状.
- 这种疗法为AH的外科干预提供了潜在的替代方案.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
375
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
375
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
358
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
358
Antiasthma Drugs: Methylxanthines
281
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
281
Antiasthma Drugs: β2-Adrenoceptor Agonists
318
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
318
Antiasthma Drugs: Muscarinic Receptor Antagonists
350
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
350
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K


